Enzyme / Abzyme Prodrug Activation Systems: Potential Use in Clinical Oncology
Journal:
Current Pharmaceutical Design
Volume:
9
Page:
2113-2130
Author(s):
Yoshisuke Nishi
Prodrugs in Genetic Chemoradiotherapy
Journal:
Current Pharmaceutical Design
Volume:
9
Page:
2131-2154
Author(s):
Adam V. Patterson, Mark P. Saunders and Olga Greco
Thirty Years of Polyamine-Related Approaches to Cancer Therapy. Retrospect and Prospect. Part 1. Selective Enzyme Inhibitors
Journal:
Current Drug Targets
Volume:
4
Page:
537-564
Author(s):
Nikolaus Seiler
Thirty Years of Polyamine-Related Approaches to Cancer Therapy. Retrospect and Prospect. Part 2. Structural Analogues and Derivatives
Journal:
Current Drug Targets
Volume:
4
Page:
565-585
Author(s):
Nikolaus Seiler
Cyclooxygenase-2 Biology
Journal:
Current Pharmaceutical Design
Volume:
9
Page:
2177-2190
Author(s):
Joan Claria
COX-2 Inhibition in Esophagitis, Barretts Esophagus and Esophageal Cancer
Journal:
Current Pharmaceutical Design
Volume:
9
Page:
2267-2280
Author(s):
E. Piazuelo, P. Jimenez and A. Lanas
Overview: Translating Hsp90 Biology into Hsp90 Drugs
Journal:
Current Cancer Drug Targets
Volume:
3
Page:
297-300
Author(s):
Paul Workman
Natural Product Origins of Hsp90 Inhibitors
Journal:
Current Cancer Drug Targets
Volume:
3
Page:
325-330
Author(s):
Yoshimasa Uehara
Development of Radicicol Analogues
Journal:
Current Cancer Drug Targets
Volume:
3
Page:
359-369
Author(s):
Shiro Soga, Yukimasa Shiotsu, Shiro Akinaga and Sreenath V. Sharma
Clinical Development of 17-Allylamino, 17-Demethoxygeldanamycin
Journal:
Current Cancer Drug Targets
Volume:
3
Page:
377-383
Author(s):
Edward A. Sausville, Joseph E. Tomaszewski and Percy Ivy